celecoxib has been researched along with ibuprofen in 206 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.94) | 18.2507 |
| 2000's | 81 (39.32) | 29.6817 |
| 2010's | 109 (52.91) | 24.3611 |
| 2020's | 12 (5.83) | 2.80 |
| Authors | Studies |
|---|---|
| Habeeb, AG; Knaus, EE; Praveen Rao, PN | 1 |
| Borst, P; de Haas, M; Kuil, A; Reid, G; van der Heijden, I; Wielinga, P; Wijnholds, J; Zelcer, N | 1 |
| Amini, M; Habeeb, AG; Knaus, EE; Li, H; Praveen Rao, PN | 1 |
| Knaus, EE; Rao, PN; Uddin, MJ | 1 |
| Chakraborti, AK; Jachak, SM; Selvam, C; Thilagavathi, R | 1 |
| Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Anderluh, M; Brunskole, M; Gobec, S; Lanisnik Rizner, T; Stefane, B; Stojan, J; Zorko, K | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR; Velázquez, C | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Rahman, M; Suresh, MR | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Knaus, EE; Suresh, MR; Velázquez, C; Yu, G | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Huang, Z; Knaus, EE; Rahman, M; Suresh, MR; Velázquez, CA; Yu, G | 1 |
| Abdellatif, KR; Chowdhury, MA; Das, D; Dong, Y; Huang, Z; Knaus, EE; Suresh, MR; Velázquez, CA; Yu, G | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bensdorf, K; Guo, C; Gust, R; Huang, W; Liu, H; Liu, W; Qian, H; Rubner, G; Wang, Y; Wellner, A; Zhang, H; Zhang, Y; Zhou, J | 1 |
| Abdellatif, KR; Chowdhury, MA; Huang, Z; Kaufman, S; Knaus, EE | 1 |
| Abdur Rahim, M; Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Praveen Rao, PN | 1 |
| Alam, MM; Alam, MS; Kalle, AM; Mulakayala, C; Mulakayala, N; Pallu, R; Shafi, S; Vanaja, G | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bhardwaj, A; Huang, Z; Kaur, J; Knaus, EE; Sharma, SK; Wuest, F | 1 |
| Bairwa, K; Grover, J; Jachak, SM; Roy, SK; Singh, IN; Srivastava, A | 1 |
| Abou-Seri, SM; Ali, MM; Hassan, GS; Kamel, G | 1 |
| Choi, HE; Choi, MJ; Jin, JH; Kang, SM; Kim, KJ; Kim, M; Lee, JY; Lee, KT; Shin, JS | 1 |
| Bairwa, K; Grover, J; Jachak, SM; Kumar, V; Singh, V; Sobhia, ME | 1 |
| Dalby, KN; Kaoud, TS; Radwan, MF | 1 |
| Govardhan Reddy, K; Kishore, B; Nagaraju, D; Rajanarendar, E; Rama Krishna, S; Reddy, YN | 1 |
| Abdellatif, KR; Azoz, AA; Elshemy, HA | 1 |
| Abdelall, EKA; Abdellatif, KRA; Fadaly, WAA; Kamel, GM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ameen, BAH; Dissanayake, AA; Nair, MG | 1 |
| Kaur, A; Pathak, DP; Sharma, V; Wakode, S | 1 |
| Boixareu, N; Campanera, JM; Navarro, L; Pors, K; Pouplana, R; Pujol, MD; Rosell, G; Sánchez, S | 1 |
| Asif, M; Husain, A; Iqbal, MA; Iram, F; Khan, SA | 1 |
| Chung, HY; Hong, J; Ju, Z; Jung, JH; Kim, S; La Kim, E; Moon, HR; Su, M | 1 |
| Neha, K; Wakode, S | 1 |
| Bai, R; Jiang, X; Wu, K; Zhang, P; Zhang, Y | 1 |
| Catella-Lawson, F; FitzGerald, GA; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF | 1 |
| Gierse, JK; Isakson, PC; Koboldt, CM; Seibert, K; Walker, MC | 1 |
| Wallace, JL | 1 |
| Dionne, R | 1 |
| Blondon, H | 1 |
| Abou-Issa, H; Alshafie, GA; Harris, RE; Seibert, K | 1 |
| Burke, A; FitzGerald, GA; Habib, A; Kapoor, S; Lawson, JA; Mardini, IA; McAdam, BF | 1 |
| Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW | 1 |
| Oberyszyn, TM; Parrett, ML; Ross, MS; Wilgus, TA | 1 |
| Tive, L | 1 |
| Browning, RA; Burgess, FW | 1 |
| Ouellet, M; Percival, MD; Riendeau, D | 1 |
| Simon, LS | 1 |
| Zuurmond, WW | 1 |
| Faich, G; Geis, GS; Lefkowith, JB; Maurath, C; Ridge, NJ; Verburg, KM; Whelton, A; White, WB | 1 |
| Connor, KE; Coppola, D; DiCarlo, G; Gordon, MN; Jantzen, PT; Morgan, D; Rojiani, AM; Wallace, JL; Wenk, GL | 1 |
| Chandra, A; Nair, MG; Schutzki, R; Seeram, NP | 1 |
| Dieppe, PA; Jüni, P; Rutjes, AW | 1 |
| Clifford, LJ; Dewitt, DL; Nair, MG; Rana, J | 1 |
| McCormack, JP; Rangno, R | 1 |
| Geis, GS | 1 |
| Brahim, JS; Dionne, RA; Khan, AA; Rowan, JS | 1 |
| Ashraf, E; Cooper, SA; Doyle, G; Jayawardena, S | 1 |
| Ekman, EF; Fiechtner, JJ; Fort, JG; Levy, S | 1 |
| Pfeifer, M | 1 |
| Arbogast, PG; Daugherty, JR; Griffin, MR; Hall, K; Ray, WA; Stein, CM | 1 |
| Fricke, JR; Kotey, P; Kress, B; Malmstrom, K; Morrison, B | 1 |
| Goldberg, J; Kenwood, A; Lavery, R; Salo, DF; Shapiro, T; Varma, V | 1 |
| Flavin, S; Haig, A; MacDonald, B; Palmer, R; Weiss, R; Zusman, RM | 1 |
| Avşar, E; Ekenel, M; Haklar, G; Imeryüz, N; Kocakaya, O; Tözün, N; Yüksel, M | 1 |
| Hawel, R; Kähler, ST; Klein, G; Mayrhofer, F; Singer, F | 1 |
| Atik, U; Burak Cimen, MY; Cimen, OB; Erdoğan, C; Eskandari, G; Sahin, G | 1 |
| Harley, C; Wagner, S | 1 |
| Burke, TA; Goldstein, JL; Henderson, SC; Palmer, R; von Allmen, H; Zhao, SZ | 1 |
| Marziniak, M; Schäfers, M; Sommer, C; Sorkin, LS; Yaksh, TL | 1 |
| Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ | 1 |
| Cryer, B; Kimmey, MB; Riff, DS; Rothstein, RI; Scheiman, JM; Wolfe, MM | 1 |
| Gotoh, T; Hoshino, T; Hwang, HJ; Mima, S; Mizushima, T; Mori, M; Takenaka, H; Tomisato, W; Tsuchiya, T; Tsutsumi, S | 1 |
| Behm, A; Cox, ER; Fairman, KA; Frisse, M | 1 |
| Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P | 1 |
| Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Berlin, JA; Chittams, J; Jaskowiak, J; Kimmel, SE; Kishel, L; Reilly, M; Strom, BL | 1 |
| Bresee, SJ; Carroll, RC; Chavez, JJ; Cohen, E; Craft, RM; Snider, CC | 1 |
| Meechan, J | 1 |
| Holt, CI; Hutchins, MO; Pileggi, R | 1 |
| Cho Han, D; Heum Park, J; Hyung Hong, S; Kim, J; Kwon, BM; Lee, SK; Min Kim, J; Miyazawa, K; Seog Yoon, K; Son, KH | 1 |
| Couzin, J | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Jacobsen, S; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Schramm, TK; Torp-Pedersen, C | 1 |
| Barner, JC; Busti, AJ; Lawson, KA; Motsko, SP; Rascati, KL; Wilson, JP; Worchel, J | 1 |
| De Clerck, L; De Keyser, F; Geusens, P; Hauzeur, JP; Luyten, FP; Malaise, M; Mathy, L; Raeman, F; Van den Bosch, F; Vander Mijnsbrugge, D; Westhovens, R | 1 |
| Castellsague, J; Maguire, A; Perez-Gutthann, S; Varas-Lorenzo, C | 1 |
| Lefkowith, JL; Verburg, KM; West, CR; Whelton, A | 1 |
| Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M | 1 |
| Bertini, S; Bonardi, S; Coruzzi, G; Giovannini, E; Grandi, D; Menozzi, A; Pozzoli, C; Solenghi, E; Vasina, V | 1 |
| Brookhart, MA; Rassen, J; Schneeweiss, S; Solomon, DH; Wang, PS | 1 |
| Kong, SX; LeLorier, J; Rahme, E; Toubouti, Y; Watson, DJ | 1 |
| Becker, TL; Gambero, A; Maróstica, M; Pedrazzoli, J | 1 |
| Hoffmeyer, P; Keller, A; Perneger, T; Riand, N; Saudan, M; Saudan, P | 1 |
| Aisenberg, J; Berger, MF; Bhadra, P; Eisen, GM; Goldstein, JL; Gralnek, IM; Lewis, B | 1 |
| Alshafie, GA; Beebe-Donk, J; Harris, RE | 1 |
| Andriulli, A; Colaizzo, D; Dallapiccola, B; Di Mario, F; Franceschi, M; Grandone, E; Leandro, G; Niro, V; Pilotto, A; Scarcelli, C; Seripa, D | 1 |
| Afshartous, D; Alonso, AB; Preston, RA | 1 |
| Dabhi, JK; Mehta, A; Solanki, JK | 1 |
| Han, JA; Kim, SR; Lee, ME; Park, JH; Park, JS; Park, SC | 1 |
| Aguiar, FA; de Souza, GE; do Vale, ML; Kanashiro, A; Machado, RR; Malvar, Ddo C; Pessini, AC; Soares, DM | 1 |
| Becker, MC; Borer, JS; Graham, DY; Husni, ME; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Mascette, AM; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, TH; Wisniewski, L; Wolski, K; Yeomans, ND | 1 |
| Choi, KH; Chung, MW; Kim, KB; Kim, SH; Lee, HJ; Oh, HY; Oh, JS; Um, SY | 1 |
| Carreras, I; Choi, JK; Cormier, K; Dedeoglu, A; Jenkins, BG; Kaymakcalan, S; Kowall, NW | 1 |
| Dolezal, T; Krsiak, M; Sliva, J; Sykora, D; Vosmanska, M | 1 |
| Arbogast, PG; Castellsague, J; Chung, CP; Daugherty, JR; García-Rodríguez, LA; Murray, KT; Ray, WA; Stein, CM; Varas-Lorenzo, C | 1 |
| De Caterina, R; Renda, G; Romano, M; Zurro, M | 1 |
| Aronoff, DM; Carlos, D; Faccioli, LH; Lourenço, EV; Machado, ER; Ramos, SG; Silva, EV; Sorgi, CA; Souza, GE; Ueta, MT | 1 |
| Guo, QL; Huang, CS; Wang, Y; Yan, JQ; Zhang, X; Zou, WY | 1 |
| Fermelia, DE; Kariger, R; Naruse, R; Sloninsky, A; Tang, J; Time, M; Tsushima, GK; Webb, T; Wender, RH; White, PF; Yumul, R; Zaentz, A; Zhao, M | 1 |
| Janovsky, M; Krsiak, M | 1 |
| Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ | 1 |
| An, H; Jiang, DM; Luo, XJ; Ou, YS; Quan, ZX; Tan, C; Tang, K | 1 |
| Borges, VF; Conklin, MW; Eliceiri, KW; Keely, PJ; Lyons, TR; Marusyk, A; O'Brien, J; Schedin, P; Tan, AC | 1 |
| Dhana, N; Jongjarearnprasert, K; Kasemsarn, P; Kulthanan, K; Tuchinda, P | 1 |
| Gaur, V; Kumar, A | 1 |
| Niebling, W | 1 |
| Al-Sukhun, J; Al-Sukhun, R; Al-Sukhun, S; Ashammakhi, N; Penttilä, H | 1 |
| Cantwell, MM; Hughes, CM; Murray, LJ; Parsons, C; Reid, J | 1 |
| An, H; Jiang, D; Luo, X; Ou, Y; Quan, Z; Tan, C; Tang, K | 1 |
| Cerna, D; Coleman, CN; Falduto, MT; J-Aryankalayil, M; Magnuson, SR; Makinde, AY; Palayoor, ST | 1 |
| Harirforoosh, S; Pettit, WL; Wyatt, JE | 1 |
| Aljadhey, H; Blalock, SJ; Brater, DC; Hansen, RA; Murray, MD; Tu, W | 1 |
| Hébert, RL; Karsh, J; Nasrallah, R; Robertson, SJ | 1 |
| Cornelius, G; Dixon, G; Fancher, RM; Ford, K; Foster, KA; Gudmundsson, OS; Hageman, MJ; Proszynski, M; Sun, H | 1 |
| Micov, AM; Stepanović-Petrović, RM; Tomić, MA | 1 |
| Charoenvilaisiri, S; Poomkokruk, A; Sakonlaya, D; Tapanadechopone, P | 1 |
| Corigliano, A; De Sarro, G; Falcone, D; Galasso, O; Gallelli, L; Gasparini, G; Greco, M; Gulletta, E; Romualdi, P; Savino, R; Southworth, S; Terracciano, R; Ventura, V | 1 |
| Aneja, A; Farkouh, ME; Gandhi, S; Greenberg, J; Iyengar, RL; Mosovich, S; Razzouk, L; Thorpe, K | 1 |
| Sifferlin, A | 1 |
| Boškovic, BD; Kovacevic, JM; Micov, AM; Stepanovic-Petrovic, RM; Tomic, MA | 1 |
| Beach, KJ; Brookhart, MA; Layton, JB; Le, HV; Poole, C; Schoenbach, VJ; Stürmer, T | 1 |
| Bhardwaj, A; Kaur, J; Knaus, EE; Wuest, F | 1 |
| Beshay, JE; Levy, M; Madden, CJ; Rickert, KL; Sarode, R; Scott, WW | 1 |
| Fukazawa, H; Inoue, M; Kaneko, Y; Miyazaki, Y; Niki, M; Ohno, H; Tanabe, K; Umeyama, T; Urai, M | 1 |
| Borba-Murad, GR; de Andrade, FG; de Fatima Silva, F; de Morais, H; de Souza, CO; de Souza, HM; Kurauti, MA | 1 |
| Caimmi, D; Caimmi, SM; Demoly, P; Manca, E; Marseglia, GL | 1 |
| Bannuru, RR; Kent, DM; McAlindon, TE; Schmid, CH; Vaysbrot, EE; Wong, JB | 1 |
| Bannon, AW; Joshi, SK; Zhu, CZ | 1 |
| Curi, R; de Morais, H; de Souza, CO; de Souza, HM; Hirabara, SM; Kurauti, MA; Rosa Neto, JC; Silva, Fde F | 1 |
| Jiang, CY; Li, FL; Li, X; Li, Y; Lu, Y; Zhuo, HW | 1 |
| Collins, JE; Hunter, DJ; Jordan, JM; Katz, JN; Losina, E; Paltiel, AD; Smith, SR; Solomon, DH; Suter, LG; Yelin, E | 1 |
| Abdelgawad, MA; Abdellatif, KR; Alsayed, SS; Elshemy, HA | 1 |
| Matteson, EL; Thongprayoon, C; Ungprasert, P | 1 |
| Doods, H; Gould, SA; Lamla, T; Pekcec, A | 1 |
| DiBattista, AM; Dumanis, SB; Newman, J; Rebeck, GW | 1 |
| Choi, KH; Chung, MW; Lee, HJ; Park, JH; Um, SY | 1 |
| Bao, W; Beckerman, B; Berger, MF; Borer, JS; Gaffney, M; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| González-Gay, MA; González-Juanatey, C | 1 |
| Nurmohamed, MT | 1 |
| Armada, B; Gordo, AC; Walker, C; Zhou, D | 1 |
| Grosser, T | 1 |
| Nissen, SE | 1 |
| Raschle, J | 1 |
| McGettigan, P; Olsen, AS | 1 |
| Nitschmann, S; Schrör, K | 1 |
| Gannon, R; O'Sullivan, DM; Reagan, KML; Steinberg, AC | 1 |
| Bauk, L; Drmic, D; Klicek, R; Kokot, A; Luetic, K; Seiwerth, S; Sikiric, P; Stupnisek, M; Vcev, A; Vitaic, S | 1 |
| Ganju, J; Rom, D | 1 |
| Baek, JS; Lee, YH; Loo, SCJ; Tan, NS; Yeo, EW | 1 |
| Borer, JS; Brennan, DM; Husni, ME; Libby, PA; Lincoff, AM; Lϋscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wisniewski, LM; Yeomans, ND | 1 |
| Cañizares, FJ; Cobos, EJ; Entrena, JM; Fernández-Segura, E; Montilla-García, Á; Perazzoli, G; Portillo-Salido, E; Tejada, MÁ | 1 |
| Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM | 1 |
| Wang, J | 1 |
| Paul, S; Sun, CC | 2 |
| Breivik, H | 1 |
| Gislason, G; Sondergaard, KB | 1 |
| Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND | 1 |
| Weintraub, WS | 1 |
| Radhakrishnan, J; Radhakrishnan, R; Yellepeddi, VK | 1 |
| Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| Chang, CH; Dong, YH; Hwang, JS; Toh, S; Wu, LC | 1 |
| Bao, W; Borer, J; Graham, DY; Husni, EM; Libby, P; Lincoff, MA; Lüscher, T; Nissen, SE; Walker, C; Wang, Q; Wisniewski, LM; Wolski, K; Yeomans, ND | 1 |
| Chang, CC; Chen, YR; Chi, NF; Chiou, HY; Hsieh, FI; Wu, HC | 1 |
| Steurer, J | 1 |
| Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND | 1 |
| Antman, EM | 1 |
| Laine, L | 1 |
| Graham, DY; Yeomans, ND | 1 |
| Baratta, JL; Dayan, AC; Pitchon, DN; Schwenk, ES; Viscusi, ER | 1 |
| Buschiazzo, HO; Cañás, M; Dorati, CM; Mordujovich-Buschiazzo, P; Prozzi, GR; Urtasun, MA | 1 |
| Akinbade, AO; Ndukwe, KC; Owotade, FJ | 1 |
| Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K | 1 |
| Cicciù, M; Isola, G; Matarese, G; Matarese, M; Ramaglia, L | 1 |
| Nissen, SE; Reed, GW | 1 |
| Açil, Y; Gülses, A; Wiltfang, J | 1 |
| Isola, G; Matarese, G | 1 |
| Agger, EM; Andersen, P; Clemmensen, HS; Dyrhol-Riise, AM; Jenum, S; Mortensen, R; Mustafa, T; Therkelsen, ML; Tonby, K; Woodworth, JS | 1 |
| Hajhashemi, V; Mesripour, A; Shahnooshi, S | 1 |
| O'Sullivan, DM; Ramaseshan, AS; Steinberg, AC; Tunitsky-Bitton, E | 1 |
| Britch, SC; Craft, RM; Hewitt, KA | 1 |
| Alonso-Castro, ÁJ; Franco-de la Torre, L; Franco-González, MA; Isiordia-Espinoza, MA | 1 |
| Dai, F; Hu, H; Li, X; Lv, Z; Ren, J; Wang, J; Zhang, B | 1 |
| Ghosh, S | 1 |
| Bao, W; Davey, DA; Husni, E; Libby, P; Lüscher, TF; Nissen, SE; Obeid, S; Ruschitzka, F; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Xia, F | 1 |
| Barakat, A; Diaz-delCastillo, M; Heegaard, AM; Rice, ASC; Sena, ES; Soliman, N; Vollert, J; Zhang, XY | 1 |
| Hjemdahl, P; Stiller, CO | 1 |
| Gorenflo, M; Saur, P; van den Anker, JN; van Dyk, M; Welzel, T; Ziesenitz, VC | 1 |
| Adema, GJ; Ansems, M; Raaijmakers, TK; Scheffer, GJ; van den Bijgaart, RJE | 1 |
19 review(s) available for celecoxib and ibuprofen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Insights into the chemistry and therapeutic potential of furanones: A versatile pharmacophore.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Molecular Structure | 2019 |
Contemporary advances of cyclic molecules proposed for inflammation.
Topics: Animals; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Humans; Inflammation; Molecular Structure; Structure-Activity Relationship | 2021 |
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Topics: Animals; Anti-Allergic Agents; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Antiviral Agents; Drug Development; Heterocyclic Compounds; Humans; Hypoglycemic Agents; Mice; Neuroprotective Agents; Photochemotherapy; Quinoxalines; Structure-Activity Relationship; Tubulin Modulators | 2022 |
Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Controlled Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etodolac; Gene Expression; Humans; Ibuprofen; Indomethacin; Isoenzymes; Meloxicam; Membrane Proteins; Naproxen; Nitrobenzenes; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thiazines; Thiazoles | 1999 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Kidney Diseases; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2000 |
COX-2 inhibitors. Are they nonsteroidal anti-inflammatory drugs with a better safety profile?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Forecasting; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2001 |
Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Cachexia; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Indomethacin; Neoplasms; Pyrazoles; Quality of Life; Sulfonamides; Treatment Outcome | 2013 |
Pharmacogenetics of nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Aspirin; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Humans; Ibuprofen; Indomethacin; Pharmacogenetics; Pyrazoles; Sulfonamides | 2012 |
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.
Topics: Acetaminophen; Adrenal Cortex Hormones; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Humans; Hyaluronic Acid; Ibuprofen; Injections, Intra-Articular; Naproxen; Osteoarthritis, Knee; Pain; Pyrazoles; Sulfonamides; Treatment Outcome; Viscosupplements | 2015 |
Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cerebral Hemorrhage; Diclofenac; Humans; Ibuprofen; Incidence; Indomethacin; Lactones; Meloxicam; Naproxen; Observational Studies as Topic; Odds Ratio; Piroxicam; Proportional Hazards Models; Stroke; Sulfones; Thiazines; Thiazoles | 2016 |
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Aspirin; Celecoxib; Child; Child, Preschool; Chronic Disease; Chronic Pain; Fenoprofen; Humans; Ibuprofen; Lactones; Meloxicam; Methoxsalen; Naproxen; Randomized Controlled Trials as Topic; Sulfones; Thiazines; Thiazoles | 2017 |
Updates on Multimodal Analgesia for Orthopedic Surgery.
Topics: Acetaminophen; Amines; Analgesia; Celecoxib; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Ibuprofen; Ketamine; Ketorolac; Orthopedic Procedures; Pain, Postoperative | 2018 |
[Cardiovascular risk of non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Drug Interactions; Humans; Ibuprofen; Naproxen; Risk Factors | 2018 |
Analgesic effectiveness and safety of celecoxib versus non-opioid active controls after third molar surgery: A meta-analytical evaluation.
Topics: Analgesics; Celecoxib; Humans; Ibuprofen; Molar, Third; Nausea; Pain, Postoperative; Vomiting | 2022 |
Metabolomic Studies for Metabolic Alterations Induced by Non-Steroidal Anti-Inflammatory Drugs: Mini Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Humans; Ibuprofen; Inflammation; Metabolome; Metabolomics | 2021 |
Systematic review and meta-analysis of studies in which burrowing behaviour was assessed in rodent models of disease-associated persistent pain.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Disease Models, Animal; Gabapentin; Ibuprofen; Male; Naproxen; Pain; Rats; Rodentia | 2022 |
Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Fibrinolytic Agents; Humans; Ibuprofen; Lactones; Naproxen; Prostaglandins; Prostaglandins I; Sulfones; Thromboxanes | 2022 |
Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Child; Chronic Disease; Diclofenac; Flurbiprofen; Humans; Ibuprofen; Infant; Ketoprofen; Ketorolac; Meloxicam; Naproxen; Niflumic Acid; Pain | 2022 |
43 trial(s) available for celecoxib and ibuprofen
| Article | Year |
|---|---|
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Duodenoscopy; Esophagoscopy; Gastric Mucosa; Gastroscopy; Humans; Ibuprofen; Lactones; Osteoarthritis; Peptic Ulcer; Placebos; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2000 |
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation.
Topics: Adult; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Eicosanoids; Female; Humans; Ibuprofen; In Vitro Techniques; Inflammation; Isoenzymes; Lipid Peroxidation; Lipopolysaccharides; Male; Membrane Proteins; Oxidative Stress; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrazoles; Sulfonamides | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Peptic Ulcer; Proportional Hazards Models; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides | 2000 |
Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Coronary Thrombosis; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Pyrazoles; Sulfonamides | 2002 |
In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model.
Topics: Adult; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Microdialysis; Molar, Third; Oral Surgical Procedures; Pain Measurement; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Substrate Specificity; Sulfonamides; Thromboxane B2; Tooth Extraction | 2002 |
Efficacy and tolerability of nonprescription ibuprofen versus celecoxib for dental pain.
Topics: Adolescent; Adult; Celecoxib; Dosage Forms; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Nonprescription Drugs; Pain, Postoperative; Pyrazoles; Sulfonamides; Time Factors; Tooth Extraction | 2002 |
Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ankle Injuries; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Double-Blind Method; Female; Humans; Ibuprofen; Male; Middle Aged; Pain Measurement; Pyrazoles; Sprains and Strains; Sulfonamides; Treatment Outcome | 2002 |
A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction | 2002 |
A randomized, clinical trial comparing oral celecoxib 200 mg, celecoxib 400 mg, and ibuprofen 600 mg for acute pain.
Topics: Acute Disease; Adult; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Ibuprofen; Male; Pain; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors | 2003 |
Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Butanones; Celecoxib; Female; Humans; Hypertension; Ibuprofen; Male; Middle Aged; Nabumetone; Pyrazoles; Sulfonamides | 2003 |
Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Double-Blind Method; Gastric Mucosa; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Permeability; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Stomach; Sucrose; Sulfonamides | 2003 |
Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Osteoarthritis, Hip; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Severity of Illness Index; Stereoisomerism; Sulfonamides; Treatment Outcome | 2003 |
In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes.
Topics: Catalase; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Erythrocytes; Free Radical Scavengers; Glutathione Peroxidase; Humans; Ibuprofen; Isoenzymes; Malondialdehyde; Meloxicam; Membrane Proteins; Middle Aged; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Superoxide Dismutase; Thiazines; Thiazoles | 2003 |
A randomized, controlled comparison of ibuprofen at the maximal over-the-counter dose compared with prescription-dose celecoxib on upper gastrointestinal mucosal injury.
Topics: Adolescent; Adult; Aged; Celecoxib; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; Female; Gastric Mucosa; Humans; Ibuprofen; Intestinal Mucosa; Male; Maximum Tolerated Dose; Middle Aged; Naproxen; Nonprescription Drugs; Probability; Pyrazoles; Reference Values; Risk Assessment; Sensitivity and Specificity; Sulfonamides | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Peptic Ulcer; Pyrazoles; Risk Factors; Sulfonamides | 2004 |
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction | 2006 |
A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibuprofen; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Pilot Projects; Prospective Studies; Pyrazoles; Statistics, Nonparametric; Sulfonamides; Treatment Outcome | 2007 |
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Edema; Female; Glomerular Filtration Rate; Heart; Humans; Hyponatremia; Ibuprofen; Kidney; Male; Middle Aged; Osteoarthritis; Pyrazoles; Sulfonamides | 2006 |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Middle Aged; Myocardial Ischemia; Osteoarthritis; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrazoles; Sulfonamides; Thromboxane B2; Treatment Outcome | 2006 |
Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Ibuprofen; Male; Middle Aged; Ossification, Heterotopic; Postoperative Care; Prospective Studies; Pyrazoles; Severity of Illness Index; Single-Blind Method; Sulfonamides | 2007 |
Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Celecoxib; Drug Therapy, Combination; Female; Humans; Ibuprofen; Intestinal Diseases; Intestinal Mucosa; Male; Middle Aged; Omeprazole; Pyrazoles; Sulfonamides | 2007 |
Effects of selective vs. nonselective cyclooxygenase inhibition on dynamic renal potassium excretion: a randomized trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Ibuprofen; Kidney; Male; Middle Aged; Models, Statistical; Potassium; Pyrazoles; Research Design; Sulfonamides; Time Factors | 2008 |
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Ibuprofen; Middle Aged; Naproxen; Prospective Studies; Pyrazoles; Sulfonamides; Treatment Outcome | 2009 |
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.
Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen; Lipoxins; Middle Aged; Myocardial Ischemia; Osteoarthritis; Placebo Effect; Pyrazoles; Sulfonamides | 2010 |
The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery.
Topics: Activities of Daily Living; Administration, Oral; Adult; Ambulatory Surgical Procedures; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chi-Square Distribution; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Ibuprofen; Italy; Los Angeles; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Placebo Effect; Prospective Studies; Pyrazoles; Recovery of Function; Sulfonamides; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2011 |
Preemptive analgesic effect of low doses of celecoxib is superior to low doses of traditional nonsteroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Ibuprofen; Least-Squares Analysis; Male; Middle Aged; Molar, Third; Pain Measurement; Pain, Postoperative; Placebos; Proportional Hazards Models; Prospective Studies; Pyrazoles; Sulfonamides; Tooth Extraction; Treatment Outcome | 2012 |
The effects of nonsteroidal anti-inflammatory drugs on clinical outcomes, synovial fluid cytokine concentration and signal transduction pathways in knee osteoarthritis. A randomized open label trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytokines; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; Osteoarthritis, Knee; Pyrazoles; Quality of Life; Signal Transduction; Sulfonamides; Synovial Fluid; Treatment Outcome | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibuprofen; Logistic Models; Male; Middle Aged; Multivariate Analysis; Naproxen; Osteoarthritis; Psychological Tests; Pyrazoles; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Assessment of common nonsteroidal anti-inflammatory medications by whole blood aggregometry: a clinical evaluation for the perioperative setting.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blood Loss, Surgical; Celecoxib; Cyclooxygenase Inhibitors; Female; Healthy Volunteers; Humans; Ibuprofen; Male; Meloxicam; Middle Aged; Naproxen; Perioperative Care; Platelet Aggregation; Pyrazoles; Sulfonamides; Thiazines; Thiazoles; Young Adult | 2014 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Intention to Treat Analysis; Kidney Diseases; Male; Middle Aged; Naproxen; Risk | 2016 |
Efficacy of celecoxib versus ibuprofen for the treatment of patients with osteoarthritis of the knee: A randomized double-blind, non-inferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Ibuprofen; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Pain; Pain Measurement; Placebos; Treatment Outcome | 2017 |
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Naproxen; Osteoarthritis; Proton Pump Inhibitors; Survival Analysis; United States; United States Food and Drug Administration | 2017 |
Decreasing postoperative narcotics in reconstructive pelvic surgery: a randomized controlled trial.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Antiemetics; Celecoxib; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Drug Utilization; Female; Gabapentin; gamma-Aminobutyric Acid; Gynecologic Surgical Procedures; Humans; Ibuprofen; Intraoperative Care; Middle Aged; Morphine; Pain Measurement; Pain, Postoperative; Postoperative Care; Premedication | 2017 |
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis | 2017 |
Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial.
Topics: Adalimumab; Aged; Antirheumatic Agents; Celecoxib; Diclofenac; Female; Humans; Hyaluronic Acid; Ibuprofen; Injections, Intra-Articular; Male; Meloxicam; Middle Aged; Osteoarthritis, Knee; Pain; Pain Measurement; Patient Safety; Pilot Projects; Severity of Illness Index; Thiazines; Thiazoles; Treatment Outcome | 2018 |
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Hypertension; Ibuprofen; Male; Naproxen; Osteoarthritis; Prospective Studies | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Kidney Diseases; Male; Middle Aged; Naproxen; Osteoarthritis; Risk Factors; Treatment Outcome | 2018 |
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroscopy; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Ibuprofen; Oxycodone; Pain, Postoperative; Recurrence; Risk Factors; Rotator Cuff Injuries; Tramadol | 2018 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspirin; Celecoxib; Double-Blind Method; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Treatment Outcome | 2018 |
Comparative Analgesic Effects of Ibuprofen, Celecoxib and Tramadol after third Molar Surgery: A Randomized Double Blind Controlled Trial.
Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Double-Blind Method; Female; Humans; Ibuprofen; Male; Mandible; Middle Aged; Molar, Third; Pain, Postoperative; Time Factors; Tooth Extraction; Tooth, Impacted; Tramadol; Treatment Outcome; Young Adult | 2018 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthritis; Reproducibility of Results; Risk Assessment; Risk Factors | 2019 |
Evaluation of the efficacy of celecoxib and ibuprofen on postoperative pain, swelling, and mouth opening after surgical removal of impacted third molars: a randomized, controlled clinical trial.
Topics: Celecoxib; Double-Blind Method; Humans; Ibuprofen; Molar, Third; Pain, Postoperative; Tooth Extraction; Tooth, Impacted | 2019 |
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Naproxen; Prospective Studies | 2022 |
144 other study(ies) available for celecoxib and ibuprofen
| Article | Year |
|---|---|
Design and synthesis of 4,5-diphenyl-4-isoxazolines: novel inhibitors of cyclooxygenase-2 with analgesic and antiinflammatory activity.
Topics: Abdominal Muscles; Androstenols; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Edema; Isoenzymes; Membrane Proteins; Models, Molecular; Muscle Contraction; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship | 2001 |
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs.
Topics: Adenosine Triphosphate; Alprostadil; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Transport; Cell Line; Cell Membrane; Diffusion; Dinoprost; Dinoprostone; Dose-Response Relationship, Drug; Humans; Insecta; Multidrug Resistance-Associated Proteins; Prostaglandins; Prostaglandins A; Prostaglandins F; Ribosomal Proteins; RNA Interference; RNA, Small Interfering; Thromboxane B2; Time Factors | 2003 |
Design, synthesis, and biological evaluation of 6-substituted-3-(4-methanesulfonylphenyl)-4-phenylpyran-2-ones: a novel class of diarylheterocyclic selective cyclooxygenase-2 inhibitors.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Design; Edema; Isoenzymes; Membrane Proteins; Models, Molecular; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrans; Pyrones; Rats; Structure-Activity Relationship; Sulfones | 2003 |
Design, synthesis, and structure-activity relationship studies of 3,4,6-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors.
Topics: Analgesics; Animals; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Edema; Isoenzymes; Membrane Proteins; Models, Molecular; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrans; Pyrones; Rats; Stereoisomerism; Structure-Activity Relationship; Sulfones | 2004 |
Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Binding Sites; Curcumin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship | 2005 |
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhibitors; Drug Design; Edema; Female; Foot; Formaldehyde; Inflammation; Male; Rats; Rats, Sprague-Dawley; Thiazoles | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Towards the first inhibitors of trihydroxynaphthalene reductase from Curvularia lunata: synthesis of artificial substrate, homology modelling and initial screening.
Topics: Amino Acid Sequence; Ascomycota; Benzopyrans; Enzyme Inhibitors; Fungal Proteins; Melanins; Models, Molecular; Molecular Sequence Data; Oxidoreductases Acting on CH-CH Group Donors; Recombinant Proteins; Structural Homology, Protein; Substrate Specificity | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-hydroxymethylphenyl)-1-(4-aminosulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its methanesulfonyl analog: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Esters; Hydrazines; Inhibitory Concentration 50; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Pyrazoles; Pyrrolidines; Rats; Sulfonamides | 2008 |
Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Acetylene; Alkynes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Ibuprofen; Inflammation; Inhibitory Concentration 50; Isoenzymes; Lipoxygenase Inhibitors; Models, Chemical; Pyridones; Rats | 2009 |
Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity.
Topics: Animals; Celecoxib; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Humans; Lipoxygenase Inhibitors; Magnetic Resonance Spectroscopy; Pyrazoles; Spectrophotometry, Infrared; Sulfonamides | 2009 |
Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Azo Compounds; Cyclooxygenase Inhibitors; Edema; Foot; Humans; Nitric Oxide; Nitric Oxide Donors; Prodrugs; Prostaglandin-Endoperoxide Synthases; Rats; Sheep | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2 Inhibitors; Humans; Hydrogen-Ion Concentration; Ibuprofen; Inhibitory Concentration 50; Molecular Structure; Nitric Oxide; Nitric Oxide Donors; Piperidines; Prodrugs; Pyrazoles; Rats; Sheep; Structure-Activity Relationship; Sulfonamides | 2010 |
Celecoxib prodrugs possessing a diazen-1-ium-1,2-diolate nitric oxide donor moiety: synthesis, biological evaluation and nitric oxide release studies.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Design; Humans; Hydrazines; Nitric Oxide; Nitric Oxide Donors; Nitrosamines; Prodrugs; Pyrazoles; Rats; Sulfonamides | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Investigations on cytotoxicity and anti-inflammatory potency of licofelone derivatives.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Edema; Female; Male; Mice; Pyrroles | 2011 |
A diazen-1-ium-1,2-diolated nitric oxide donor ester prodrug of 3-(4-hydroxymethylphenyl)-4-(4-methanesulfonylphenyl)-5H-furan-2-one: synthesis, biological evaluation and nitric oxide release studies.
Topics: 4-Butyrolactone; Animals; Cyclooxygenase 2 Inhibitors; Esters; Inhibitory Concentration 50; Mesenteric Arteries; Molecular Structure; Nitric Oxide Donors; Prodrugs; Rats; Sulfones; Triazenes | 2011 |
Isomeric acetoxy analogs of celecoxib and their evaluation as cyclooxygenase inhibitors.
Topics: Animals; Anti-Inflammatory Agents; Catalytic Domain; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Humans; Models, Molecular; Pyrazoles; Rats; Sulfonamides | 2011 |
Synthesis of novel 2-mercapto benzothiazole and 1,2,3-triazole based bis-heterocycles: their anti-inflammatory and anti-nociceptive activities.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Benzothiazoles; Click Chemistry; Cyclooxygenase Inhibitors; Edema; Female; Humans; Male; Models, Molecular; Nociception; Rats; Rats, Wistar; Triazoles | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Hybrid fluorescent conjugates of COX-2 inhibitors: search for a COX-2 isozyme imaging cancer biomarker.
Topics: Acridines; Acridones; Biomarkers, Tumor; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Fluorescent Dyes; Humans; Ibuprofen; Microscopy, Confocal; Protein Binding; Pyrazoles; Rhodamines; Structure-Activity Relationship; Sulfonamides | 2013 |
Rotenoids from Boerhaavia diffusa as potential anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Female; Flavonoids; India; Molecular Structure; Nyctaginaceae; Plant Roots; Rats; Rats, Sprague-Dawley; Rotenone | 2013 |
Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evaluation as potential anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Benzofurans; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Drug Evaluation, Preclinical; Magnetic Resonance Spectroscopy; Male; Molecular Docking Simulation; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2014 |
Synthesis, biological evaluation, and docking analysis of a novel family of 1-methyl-1H-pyrrole-2,5-diones as highly potent and selective cyclooxygenase-2 (COX-2) inhibitors.
Topics: Anti-Inflammatory Agents; Benzoquinones; Binding Sites; Catalytic Domain; Cell Survival; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Hydrogen Bonding; Inhibitory Concentration 50; Macrophages; Models, Molecular; Molecular Docking Simulation; Protein Binding; Pyrroles; Structure-Activity Relationship | 2014 |
Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors.
Topics: Absorption, Physicochemical; Animals; Anthraquinones; Catalytic Domain; Chemistry Techniques, Synthetic; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Inhibitory Concentration 50; Molecular Docking Simulation; Naphthalenes; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2014 |
Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors.
Topics: | 2014 |
Environmentally benign synthesis, molecular properties prediction and anti-inflammatory activity of novel isoxazolo[5,4-d]isoxazol-3-yl-aryl-methanones via vinylogous Henry nitroaldol adducts as synthons.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Edema; Heterocyclic Compounds, 3-Ring; Isoxazoles; Molecular Structure; Nitro Compounds; Rats; Rats, Wistar; Structure-Activity Relationship | 2015 |
1-(4-Methane(amino)sulfonylphenyl)-3-(4-substituted-phenyl)-5-(4-trifluoromethylphenyl)-1H-2-pyrazolines/pyrazoles as potential anti-inflammatory agents.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Pyrazoles; Structure-Activity Relationship | 2015 |
Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,3,5-triarylpyrazoline and 1,5-diarylpyrazole derivatives as selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Pyrazoles; Ulcer | 2016 |
Lipid Peroxidation and Cyclooxygenase Enzyme Inhibitory Compounds from Prangos haussknechtii.
Topics: Anti-Inflammatory Agents; Antioxidants; Coumarins; Cyclooxygenase Inhibitors; Lipid Peroxidation; Molecular Structure; Plant Extracts; Tetrazoles; Tetrazolium Salts; Thiazoles | 2017 |
Synthesis, biological evaluation and docking study of a new series of di-substituted benzoxazole derivatives as selective COX-2 inhibitors and anti-inflammatory agents.
Topics: Animals; Anti-Inflammatory Agents; Benzoxazoles; Binding Sites; Catalytic Domain; Cattle; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Edema; Half-Life; Humans; Molecular Docking Simulation; Rats; Rats, Wistar; Structure-Activity Relationship | 2018 |
Synthesis and biological properties of aryl methyl sulfones.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Carrageenan; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Edema; Humans; Male; Mice; Models, Molecular; Molecular Structure; Rats; Rats, Sprague-Dawley; Stomach Ulcer; Structure-Activity Relationship; Sulfones; Thermodynamics | 2018 |
Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Mice; Models, Molecular; Molecular Structure; RAW 264.7 Cells; Sheep; Structure-Activity Relationship; Urochordata | 2019 |
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Epoprostenol; Female; Humans; Ibuprofen; Isoenzymes; Male; Membrane Proteins; Middle Aged; Monocytes; Platelet Aggregation; Platelet Aggregation Inhibitors; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thromboxane B2 | 1999 |
Kinetic basis for selective inhibition of cyclo-oxygenases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Humans; Ibuprofen; Indomethacin; Inhibitory Concentration 50; Isoenzymes; Kinetics; Male; Membrane Proteins; Mice; Naproxen; Oxygen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Structure-Activity Relationship; Sulfonamides; Tetramethylphenylenediamine; Thermodynamics | 1999 |
COX-2 inhibitors: better than ibuprofen for dental pain?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Ibuprofen; Isoenzymes; Lactones; Membrane Proteins; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Toothache | 1999 |
Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Body Weight; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Ibuprofen; Isoenzymes; Mammary Neoplasms, Animal; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Substrate Specificity; Sulfonamides | 2000 |
Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation.
Topics: Administration, Topical; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dermatitis; Dinoprostone; Edema; Epidermis; Female; Ibuprofen; Isoenzymes; Mice; Mice, Hairless; Neutrophils; Peroxidase; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Skin; Sulfonamides; Sunburn; Ultraviolet Rays | 2000 |
Nonsteroidal anti-inflammatory drugs for perioperative pain control.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Etodolac; Humans; Ibuprofen; Indomethacin; Ketorolac; Lactones; Nabumetone; Naproxen; Pain, Postoperative; Piroxicam; Pyrazoles; Sulfonamides; Sulfones; Time Factors | 2001 |
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones | 2001 |
[Side effects cause enormous costs. Expensive arthritis therapy].
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Celecoxib; Cyclooxygenase Inhibitors; Drug Costs; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Nabumetone; Patient Satisfaction; Pyrazoles; Sulfonamides; Sulfones | 2001 |
Pain treatment with NSAIDs, primary focus on ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Ibuprofen; Pain; Pyrazoles; Sulfonamides | 2001 |
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Differentiation; Celecoxib; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Flurbiprofen; Frontal Lobe; Hippocampus; Histocompatibility Antigens Class II; Ibuprofen; Membrane Proteins; Mice; Mice, Transgenic; Microglia; Nitric Oxide; Presenilin-1; Pyrazoles; Sulfonamides; Treatment Outcome | 2002 |
Characterization, quantification, and bioactivities of anthocyanins in Cornus species.
Topics: Anthocyanins; Antioxidants; Celecoxib; Chromatography, High Pressure Liquid; Cornus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fruit; Ibuprofen; Isoenzymes; Lactones; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Ibuprofen; Isoenzymes; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Research Design; Stomach Ulcer; Sulfonamides | 2002 |
Bioactivity of alkamides isolated from Echinacea purpurea (L.) Moench.
Topics: Aedes; Amides; Animals; Anti-Inflammatory Agents; Aspirin; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Echinacea; Ibuprofen; Isoenzymes; Lactones; Lethal Dose 50; Naproxen; Phytotherapy; Plant Extracts; Plant Roots; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones | 2002 |
Digging for data from the COX-2 trials.
Topics: Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Treatment Outcome | 2002 |
Are selective COX 2 inhibitors superior to traditional NSAIDs? Pharmacia's response to editorial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Diclofenac; Drug Therapy, Combination; Humans; Ibuprofen; Peptic Ulcer; Pyrazoles; Sulfonamides | 2002 |
[Analgesic in osteoporosis. Why so conservative with dosage?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Humans; Ibuprofen; Lactones; Middle Aged; Osteoporosis; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2002 |
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Coronary Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Ibuprofen; Isoenzymes; Lactones; Male; Medicaid; Membrane Proteins; Middle Aged; Naproxen; Product Surveillance, Postmarketing; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones; Tennessee | 2002 |
[Rapid, strong and long-term effectiveness. Coxib also effective in toothache].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Ibuprofen; Isoenzymes; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Tooth Extraction; Toothache; Treatment Outcome | 2003 |
Persistence with COX-2 inhibitors in managed care: an analysis of claims data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Utilization Review; Female; Health Care Costs; Humans; Ibuprofen; Insurance Claim Review; Isoenzymes; Lactones; Male; Managed Care Programs; Membrane Proteins; Middle Aged; Naproxen; Patient Compliance; Proportional Hazards Models; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Regression Analysis; Sulfonamides; Sulfones; United States | 2003 |
Incidence of outpatient physician claims for upper gastrointestinal symptoms among new users of celecoxib, ibuprofen, and naproxen in an insured population in the United States.
Topics: Abdominal Pain; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Dyspepsia; Female; Humans; Ibuprofen; Incidence; Insurance Claim Reporting; Male; Middle Aged; Naproxen; Nausea; Outpatients; Poisson Distribution; Proportional Hazards Models; Pyrazoles; Risk Factors; Sulfonamides; United States; Vomiting | 2003 |
Cyclooxygenase inhibition in nerve-injury- and TNF-induced hyperalgesia in the rat.
Topics: Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Ganglia, Spinal; Hyperalgesia; Ibuprofen; Isoenzymes; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sciatic Neuropathy; Spinal Cord; Sulfonamides; Tumor Necrosis Factor-alpha | 2004 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Fibromyalgia; Follow-Up Studies; Humans; Ibuprofen; Isoenzymes; Lactones; Longitudinal Studies; Male; Membrane Proteins; Middle Aged; Naproxen; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Surveys and Questionnaires | 2004 |
Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis.
Topics: Activating Transcription Factor 4; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Northern; Celecoxib; Cell Line; Cell Survival; Cells, Cultured; Diclofenac; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Gastric Mucosa; Genes, Reporter; Guinea Pigs; Heat-Shock Proteins; Hydrogen Peroxide; Ibuprofen; Immunoblotting; Indomethacin; Luciferases; Macrophages; Microscopy, Fluorescence; Molecular Chaperones; Plasmids; Pyrazoles; Regulatory Factor X Transcription Factors; RNA, Messenger; Sulfonamides; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; X-Box Binding Protein 1 | 2004 |
Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nonprescription Drugs; Pyrazoles; Sulfonamides | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Flurbiprofen; Ibuprofen; Isoenzymes; Lactones; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides; Sulfones; Thrombosis | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bias; Case-Control Studies; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Risk Factors; Sulfonamides; Sulfones | 2005 |
A Thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Celecoxib; Dose-Response Relationship, Drug; Humans; Ibuprofen; Platelet Activation; Platelet Aggregation; Pyrazoles; Sulfonamides; Thrombelastography | 2005 |
A real time quantitative PCR analysis and correlation of COX-1 and COX-2 enzymes in inflamed dental pulps following administration of three different NSAIDs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dental Pulp Exposure; Ibuprofen; Lactones; Male; Pulpitis; Pyrazoles; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Sulfones | 2005 |
Differential regulation of anti-inflammatory proteins in human rheumatoid synoviocyte MH7A cell by celecoxib and ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cell Line; Electrophoresis, Gel, Two-Dimensional; Humans; Ibuprofen; Mass Spectrometry; Protein Biosynthesis; Pyrazoles; Sulfonamides; Synovial Membrane | 2006 |
Drug testing. Massive trial of Celebrex seeks to settle safety concerns.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Interactions; Heart Diseases; Humans; Ibuprofen; Membrane Proteins; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides | 2005 |
Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Confidence Intervals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Denmark; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Readmission; Proportional Hazards Models; Pyrazoles; Recurrence; Registries; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones | 2006 |
Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk.
Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Etodolac; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Naproxen; Pyrazoles; Sulfonamides; Sulfones; Time Factors; United States; Veterans | 2006 |
Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Computer Simulation; Coronary Disease; Cyclooxygenase Inhibitors; Diclofenac; Female; Heart Failure; Humans; Ibuprofen; Male; Middle Aged; Models, Statistical; Naproxen; Peptic Ulcer; Population Surveillance; Pyrazoles; Risk Assessment; Risk Factors; Stroke; Sulfonamides; United States | 2007 |
Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat.
Topics: Administration, Oral; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Enterobacteriaceae; Ibuprofen; Indomethacin; Intestinal Mucosa; Intestine, Small; Lipid Peroxidation; Male; Mucins; Peroxidase; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2006 |
Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Lactones; Male; Multivariate Analysis; Myocardial Infarction; Naproxen; Pyrazoles; Rheumatic Diseases; Risk Assessment; Risk Factors; Sulfonamides; Sulfones | 2006 |
Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Prescriptions; Drug Utilization; Female; Hospitalization; Humans; Ibuprofen; Lactones; Male; Myocardial Infarction; Product Surveillance, Postmarketing; Proportional Hazards Models; Pyrazoles; Quebec; Retrospective Studies; Sex Factors; Sulfonamides; Sulfones | 2007 |
Effect of different cyclooxygenase inhibitors on gastric adaptive cytoprotection induced by 20% ethanol.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytoprotection; Diclofenac; Dinoprostone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ethanol; Gastric Acid; Gastric Mucosa; Ibuprofen; Irritants; Male; Meloxicam; Membrane Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pyrazoles; Rats; Rats, Wistar; Stomach Ulcer; Sulfonamides; Thiazines; Thiazoles | 2007 |
Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Celecoxib; Chemoprevention; Cyclooxygenase 2 Inhibitors; Female; Humans; Ibuprofen; Lactones; Logistic Models; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Ohio; Pyrazoles; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones | 2007 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Celecoxib; Cytochrome P-450 CYP2C9; Diclofenac; Female; Gene Frequency; Genetic Predisposition to Disease; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Odds Ratio; Peptic Ulcer; Peptic Ulcer Hemorrhage; Piroxicam; Polymorphism, Single Nucleotide; Pyrazoles; Risk Assessment; Risk Factors; Sulfonamides | 2007 |
Antiatherosclerotic activity of ibuprofen, a non-selective COX inhibitor--an animal study.
Topics: Animals; Anti-Inflammatory Agents; Antiparasitic Agents; Aspirin; Atherosclerosis; Celecoxib; Disease Models, Animal; Female; Hypercholesterolemia; Hypolipidemic Agents; Ibuprofen; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Sulfonamides | 2008 |
Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner.
Topics: Aspirin; Caveolin 1; Celecoxib; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fibroblasts; Flurbiprofen; Humans; Ibuprofen; Kinetics; Models, Biological; NF-kappa B; Nitrobenzenes; Pyrazoles; Reactive Oxygen Species; Skin; Skin Aging; Sulfonamides; Tumor Suppressor Protein p53 | 2008 |
Characterization and pharmacological evaluation of febrile response on zymosan-induced arthritis in rats.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Body Temperature; Celecoxib; Dexamethasone; Dinoprostone; Dipyrone; Dose-Response Relationship, Drug; Fever; Ibuprofen; Injections, Intra-Articular; Male; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Zymosan | 2009 |
Pattern recognition analysis for the prediction of adverse effects by nonsteroidal anti-inflammatory drugs using 1H NMR-based metabolomics in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Ibuprofen; Indomethacin; Least-Squares Analysis; Magnetic Resonance Spectroscopy; Male; Metabolomics; Pattern Recognition, Automated; Predictive Value of Tests; Pyrazoles; Rats; Rats, Sprague-Dawley; Stomach; Sulfonamides | 2009 |
Anti-inflammatory treatment in AD mice protects against neuronal pathology.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Female; Frontal Lobe; Hippocampus; Humans; Ibuprofen; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Transgenic; Presenilins; Pyrazoles; Sulfonamides | 2010 |
Guaifenesin enhances the analgesic potency of ibuprofen, nimesulide and celecoxib in mice.
Topics: Acetic Acid; Analgesia; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Synergism; Expectorants; Guaifenesin; Ibuprofen; Male; Mice; Pain; Pain Measurement; Pyrazoles; Sulfonamides | 2009 |
Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cohort Studies; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Follow-Up Studies; Hospitalization; Humans; Ibuprofen; Incidence; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Outpatients; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; Tennessee | 2009 |
Cyclooxygenase-derived mediators regulate the immunological control of Strongyloides venezuelensis infection.
Topics: Animals; Ascitic Fluid; Blood; Bronchoalveolar Lavage Fluid; Celecoxib; Dinoprostone; Duodenum; Enzyme Inhibitors; Eosinophils; Ibuprofen; Indomethacin; Leukocytes, Mononuclear; Lung; Male; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rats; Rats, Wistar; Strongyloides; Strongyloidiasis; Sulfonamides; Th1 Cells; Th2 Cells | 2010 |
Cyclooxygenase inhibitors suppress the expression of P2X(3) receptors in the DRG and attenuate hyperalgesia following chronic constriction injury in rats.
Topics: Animals; Celecoxib; Constriction, Pathologic; Cyclooxygenase Inhibitors; Ganglia, Spinal; Hot Temperature; Hyperalgesia; Ibuprofen; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P2; Receptors, Purinergic P2X3; Sciatic Nerve; Sulfonamides; Touch | 2010 |
Codeine did not increase analgesic efficacy of coxibs in contrast to that of paracetamol or ibuprofen: isobolographic analysis in mice.
Topics: Acetaminophen; Acetic Acid; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Celecoxib; Codeine; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Etoricoxib; Ibuprofen; Male; Mice; Mice, Inbred Strains; Models, Animal; Pain; Pyrazoles; Pyridines; Regression Analysis; Sulfonamides; Sulfones | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Confounding Factors, Epidemiologic; Coronary Artery Disease; Diclofenac; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypertension; Ibuprofen; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Myocardial Infarction; Naproxen; Odds Ratio; Proportional Hazards Models; Pyrazoles; Randomized Controlled Trials as Topic; Stroke; Sulfonamides; Verapamil | 2011 |
The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Chondrocytes; Collagen Type I; Collagen Type II; Collagen Type III; Disease Models, Animal; Ibuprofen; Immunohistochemistry; Indomethacin; Osteoarthritis; Proteoglycans; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Time Factors | 2012 |
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.
Topics: Analysis of Variance; Animals; Blotting, Western; Breast Neoplasms; Carcinoma, Ductal; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Disease Models, Animal; Female; Fibrillar Collagens; Humans; Ibuprofen; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mammary Glands, Animal; Mice; Mice, SCID; Neoplasm Invasiveness; Postpartum Period; Pregnancy; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2011 |
Cutaneous reactions to non-steroidal anti-inflammatory drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Ibuprofen; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sulfonamides; Urticaria; Young Adult | 2011 |
Effect of nonselective and selective COX-2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Celecoxib; Cyclooxygenase 2 Inhibitors; Glutathione; Hippocampus; Ibuprofen; Male; Maze Learning; Memory Disorders; Pyrazoles; Rats; Rats, Wistar; Reperfusion Injury; Sulfonamides; Tumor Necrosis Factor-alpha | 2012 |
[Bringing evidence to practice: obstacles and barriers].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comparative Effectiveness Research; Conflict of Interest; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Approval; Drug Industry; Evidence-Based Medicine; Germany; Humans; Ibuprofen; Peptic Ulcer; Practice Guidelines as Topic; Publication Bias; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Research Support as Topic; Sulfonamides; Translational Research, Biomedical | 2011 |
Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte.
Topics: Animals; Apoptosis; Cartilage, Articular; Celecoxib; Chondrocytes; Collagen Type II; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Humans; Ibuprofen; Indomethacin; Osteoarthritis; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2012 |
Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Celecoxib; Cell Proliferation; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Humans; Ibuprofen; Microarray Analysis; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Nitrobenzenes; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2012 |
Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Drug Interactions; Female; Humans; Hypertension; Ibuprofen; Indiana; Linear Models; Male; Middle Aged; Naproxen; Odds Ratio; Propensity Score; Pyrazoles; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Treatment Outcome | 2012 |
Celecoxib modifies glomerular basement membrane, mesangium and podocytes in OVE26 mice, but ibuprofen is more detrimental.
Topics: Albumins; Animals; Blood Glucose; Blood Pressure; Celecoxib; Creatinine; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Basement Membrane; Glomerular Mesangium; Ibuprofen; Male; Mice; Mice, Inbred Strains; Podocytes; Prostaglandins; Pyrazoles; Sulfonamides; Transforming Growth Factor beta | 2013 |
Utility of gastric-retained alginate gels to modulate pharmacokinetic profiles in rats.
Topics: Administration, Oral; Alginates; Animals; Antihypertensive Agents; Celecoxib; Cyclooxygenase Inhibitors; Delayed-Action Preparations; Gastric Mucosa; Gels; Glucuronic Acid; Hexuronic Acids; Ibuprofen; Male; Metoprolol; Permeability; Pyrazoles; Rats; Rats, Sprague-Dawley; Solubility; Sulfonamides | 2013 |
Levetiracetam interacts synergistically with nonsteroidal analgesics and caffeine to produce antihyperalgesia in rats.
Topics: Acetaminophen; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Celecoxib; Drug Synergism; Drug Therapy, Combination; Hyperalgesia; Ibuprofen; Inflammation; Levetiracetam; Male; Piracetam; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2013 |
Do NSAIDs inhibit growth of precancerous cervical cells in vitro?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Line; Cell Proliferation; Cervix Uteri; Drug Screening Assays, Antitumor; Female; Humans; Ibuprofen; Precancerous Conditions; Pyrazoles; Sulfonamides; Uterine Cervical Neoplasms | 2012 |
More pain for painkillers.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Naproxen; Pain; Pyrazoles; Risk Factors; Safety-Based Drug Withdrawals; Sulfonamides; United States; United States Food and Drug Administration | 2013 |
Antihyperalgesic/antinociceptive effects of ceftriaxone and its synergistic interactions with different analgesics in inflammatory pain in rodents.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Animals; Anti-Bacterial Agents; Ceftriaxone; Celecoxib; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hyperalgesia; Ibuprofen; Inflammation; Levetiracetam; Male; Pain; Piracetam; Pyrazoles; Rats; Rats, Wistar; Sulfonamides | 2014 |
Effects of aggregation of drug and diagnostic codes on the performance of the high-dimensional propensity score algorithm: an empirical example.
Topics: Adolescent; Adult; Aged; Algorithms; Arthritis; Celecoxib; Confounding Factors, Epidemiologic; Cyclooxygenase 2 Inhibitors; Diclofenac; Gastrointestinal Diseases; Hemorrhage; Humans; Ibuprofen; Incidence; Middle Aged; Models, Statistical; Prevalence; Propensity Score; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Fluorophore-labeled cyclooxygenase-2 inhibitors for the imaging of cyclooxygenase-2 overexpression in cancer: synthesis and biological studies.
Topics: 4-Chloro-7-nitrobenzofurazan; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Colonic Neoplasms; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Fluorescent Dyes; HCT116 Cells; Humans; Ibuprofen; Microscopy, Confocal; Naproxen; Protein Binding; Pyrazoles; Sulfonamides | 2014 |
Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action.
Topics: Antifungal Agents; ATP-Binding Cassette Transporters; Candida albicans; Candidiasis; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Fluconazole; Fungal Proteins; Gene Expression; Ibuprofen; Membrane Transport Proteins; Microbial Sensitivity Tests; Omeprazole; Phenylpropionates; Proton Pump Inhibitors | 2014 |
Effects of celecoxib and ibuprofen on metabolic disorders induced by Walker-256 tumor in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cachexia; Carcinoma 256, Walker; Celecoxib; Cell Line, Tumor; Eating; Ibuprofen; Intra-Abdominal Fat; Male; Neoplasm Transplantation; Organ Size; Pyrazoles; Rats, Wistar; Sulfonamides; Weight Loss | 2015 |
NSAID hypersensitivity in twins.
Topics: Adolescent; Allergens; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Celecoxib; Child; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Drug Hypersensitivity; Female; Gene-Environment Interaction; Genetic Predisposition to Disease; Humans; Ibuprofen; Immunization; Immunoglobulin E; Piroxicam; Pyrazoles; Sulfonamides; Twins; Urticaria | 2014 |
Complete Freund's adjuvant-induced reduction of exploratory activity in a novel environment as an objective nociceptive endpoint for sub-acute inflammatory pain model in rats.
Topics: Adjuvants, Immunologic; Amines; Analgesics; Animals; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diclofenac; Disease Models, Animal; Duloxetine Hydrochloride; Exploratory Behavior; Freund's Adjuvant; Gabapentin; gamma-Aminobutyric Acid; Ibuprofen; Male; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley | 2015 |
Celecoxib and Ibuprofen Restore the ATP Content and the Gluconeogenesis Activity in the Liver of Walker-256 Tumor-Bearing Rats.
Topics: Adenosine Triphosphate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Gluconeogenesis; Ibuprofen; Liver; Male; Neoplasms; Rats; Rats, Wistar | 2015 |
Do Different Cyclooxygenase Inhibitors Impair Rotator Cuff Healing in a Rabbit Model?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Celecoxib; Cyclooxygenase 2 Inhibitors; Flurbiprofen; Ibuprofen; Male; Rabbits; Rotator Cuff; Tendon Injuries; Wound Healing | 2015 |
Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Comorbidity; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Services Research; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Nonprescription Drugs; Osteoarthritis, Knee; Pain; Pain Measurement; Proton Pump Inhibitors; Quality-Adjusted Life Years; Sensitivity and Specificity; Tramadol; Treatment Outcome; United States | 2016 |
Design, synthesis and biological screening of new 4-thiazolidinone derivatives with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Edema; Humans; Ibuprofen; Mice; Molecular Docking Simulation; Sheep; Stomach Ulcer; Sulfonamides; Thiazolidines | 2016 |
Pharmacological characterization of intraplantar Complete Freund's Adjuvant-induced burrowing deficits.
Topics: Amines; Analgesics; Animals; Antibodies; Behavior, Animal; Celecoxib; Cyclohexanecarboxylic Acids; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; Freund's Adjuvant; Gabapentin; gamma-Aminobutyric Acid; Ibuprofen; Indomethacin; Inflammation; Male; Morphine; Motor Activity; Nerve Growth Factor; Pain; Rats, Wistar; Tramadol | 2016 |
Identification and modification of amyloid-independent phenotypes of APOE4 mice.
Topics: Age Factors; Alzheimer Disease; Amyloid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein E4; Brain; Celecoxib; Cyclooxygenase 2 Inhibitors; Dendritic Spines; Disease Models, Animal; Female; Genotype; Humans; Hypoglycemic Agents; Ibuprofen; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurons; Phenotype; Pioglitazone; Protein Processing, Post-Translational; Thiazolidinediones | 2016 |
(1)H-Nuclear magnetic resonance-based metabolic profiling of nonsteroidal anti-inflammatory drug-induced adverse effects in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Gastric Mucosa; Ibuprofen; Indomethacin; Least-Squares Analysis; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Metabolomics; Piroxicam; Rats; Rats, Sprague-Dawley | 2016 |
Inflammation: NSAIDs and cardiovascular risk in arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Inflammation; Naproxen; Risk Factors | 2017 |
Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen; Osteoarthritis; Outcome Assessment, Health Care; Safety | 2017 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Humans; Ibuprofen; Naproxen; Pyrazoles; Sulfonamides | 2017 |
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Humans; Ibuprofen; Naproxen; Pyrazoles; Sulfonamides | 2017 |
NSAIDs for high-risk patients: none, celecoxib, or naproxen?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen; Pyrazoles; Sulfonamides | 2017 |
[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Double-Blind Method; Humans; Ibuprofen; Naproxen; Prospective Studies; Pyrazoles; Sulfonamides | 2017 |
Nonsteroidal anti-inflammatory drugs-induced failure of lower esophageal and pyloric sphincter and counteraction of sphincters failure with stable gatric pentadecapeptide BPC 157 in rats.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Celecoxib; Diclofenac; Esophageal Sphincter, Lower; Ibuprofen; Male; Peptide Fragments; Pressure; Proteins; Pylorus; Rats, Wistar | 2017 |
Non-inferiority versus superiority drug claims: the (not so) subtle distinction.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Drug Approval; Drug Therapy; Equivalence Trials as Topic; Humans; Ibuprofen; Models, Statistical; Naproxen; Research Design; Risk Assessment; Risk Factors; Treatment Outcome | 2017 |
Controlled-release nanoencapsulating microcapsules to combat inflammatory diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Capsules; Celecoxib; Cimetidine; Delayed-Action Preparations; Diffusion; Drug Combinations; Drug Compounding; Drug Liberation; Drug Stability; Gastric Juice; Histamine H2 Antagonists; Ibuprofen; Inflammation; Kinetics; Models, Chemical; Nanocapsules; Nanotechnology; Naproxen; Polymers; Solubility; Technology, Pharmaceutical | 2017 |
Grip strength in mice with joint inflammation: A rheumatology function test sensitive to pain and analgesia.
Topics: Acetaminophen; Analgesics; Animals; Arthritis; Celecoxib; Disease Models, Animal; Diterpenes; Female; Freund's Adjuvant; Hand Strength; Hyperalgesia; Ibuprofen; Inflammation; Muscle Strength; Nociceptors; Oxycodone; Pain Measurement; Rheumatic Diseases; Ruthenium Red; Tarsus, Animal; Touch; Tramadol; TRPV Cation Channels | 2017 |
The suitability of common compressibility equations for characterizing plasticity of diverse powders.
Topics: Algorithms; Calcium Phosphates; Celecoxib; Cellulose; Compressive Strength; Excipients; Hardness; Ibuprofen; Lactose; Mannitol; Powders; Stearic Acids | 2017 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network Meta-Analysis; Osteoarthritis; Pain | 2017 |
NSAIDs and cardiac arrest: Non-steroidal anti-inflammatory drug use is associated with increased risk of Out-of-hospital Cardiac Arrest: A nationwide Case-Time-Control study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Denmark; Humans; Ibuprofen; Lactones; Naproxen; Out-of-Hospital Cardiac Arrest; Risk Factors; Sulfones | 2017 |
Safety of non-steroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Celecoxib; Humans; Ibuprofen; Naproxen; Prospective Studies | 2017 |
Penetration and pharmacokinetics of non-steroidal anti-inflammatory drugs in rat prostate tissue.
Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Celecoxib; Chromatography, Liquid; Comparative Effectiveness Research; Diclofenac; Disease Models, Animal; Ibuprofen; Inflammation; Male; Naproxen; Pelvic Pain; Prostate; Prostatitis; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2018 |
Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Pharmaceutical; Diclofenac; Female; Hospitalization; Humans; Hypertension; Ibuprofen; Male; Mefenamic Acid; Middle Aged; Naproxen; Risk Factors | 2018 |
Acute pancreatitis with long-term celecoxib vs. ibuprofen or naproxen: data from the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Celecoxib; Humans; Ibuprofen; Naproxen; Pancreatitis; Risk; Taiwan | 2018 |
Effect on Risk of Stroke and Acute Myocardial Infarction of Nonselective Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Diclofenac; Female; Humans; Ibuprofen; Logistic Models; Male; Mefenamic Acid; Meloxicam; Middle Aged; Myocardial Infarction; Odds Ratio; Risk Factors; Stroke | 2018 |
Modulating Sticking Propensity of Pharmaceuticals Through Excipient Selection in a Direct Compression Tablet Formulation.
Topics: Adhesiveness; Celecoxib; Drug Compounding; Excipients; Ibuprofen; Powders; Tablets | 2018 |
The Aspirin-NSAID Interaction: More Data, But a Lack of Clarity Remains.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Ibuprofen; Naproxen | 2018 |
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen | 2018 |
Editorial: gastrointestinal safety of COX-2 selective and nonselective NSAIDs-the impact of the PRECISION trial. Authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Naproxen | 2018 |
NSAID choice: lessons from PRECISION.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Humans; Ibuprofen; Naproxen; Pain; Treatment Outcome | 2019 |
Danger of highlighting the use of coxibs in daily dental practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Molar, Third; Pain, Postoperative | 2019 |
In response to Letter to the Editor "Danger of highlighting the use of coxibs in daily dental practice".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Ibuprofen; Molar, Third; Pain, Postoperative | 2019 |
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate
Topics: Adoptive Transfer; Aerosols; Animals; Bacterial Load; Celecoxib; Cell Differentiation; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Disease Progression; Female; Host-Pathogen Interactions; Ibuprofen; Inhalation Exposure; Interferon-gamma; Lung; Lymphocyte Activation; Mice, Inbred C3H; Mycobacterium tuberculosis; Th1 Cells; Tuberculosis, Pulmonary | 2019 |
Celecoxib, ibuprofen, and indomethacin alleviate depression-like behavior induced by interferon-alfa in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Celecoxib; Depression; Disease Models, Animal; Exercise Test; Ibuprofen; Indomethacin; Interferon-alpha; Male; Mice | 2019 |
A comprehensive model for pain management in patients undergoing pelvic reconstructive surgery: a prospective clinical practice study.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Enhanced Recovery After Surgery; Female; Gabapentin; Gynecologic Surgical Procedures; Humans; Ibuprofen; Middle Aged; Oxycodone; Pain Management; Pain, Postoperative; Pelvic Organ Prolapse; Perioperative Care; Plastic Surgery Procedures; Prospective Studies | 2020 |
Antinociception produced by nonsteroidal anti-inflammatory drugs in female vs male rats.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; Hyperalgesia; Ibuprofen; Inflammation; Ketoprofen; Male; Pain; Rats; Rats, Sprague-Dawley; Sex Factors | 2021 |
Hydrophilic polymer driven crystallization self-assembly: an inflammatory multi-drug combination nanosystem against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Cell Line; Crystallization; Drug Design; Humans; Ibuprofen; Male; Mice; Micelles; Molecular Structure; Nanostructures; Neuroinflammatory Diseases; Polymers; Telmisartan | 2021 |
NSAIDs affect dendritic cell cytokine production.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Neoplasm; CD8-Positive T-Lymphocytes; Celecoxib; Cytokines; Dendritic Cells; Diclofenac; Humans; Ibuprofen; Mice; Neoplasms | 2022 |